Login
$ANGO
$11.78 -$0.09 (0.76%) Live

$ANGO 8-K SEC Filings

Filed On Filing
08 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

This Employment Agreement (the “Agreement”) is entered into by and between AngioDynamics, Inc, a Delaware corporation (the “Company”) and Eric Honroth (“Executive”) (together, the “Parties” and individually, a “Party”).

14 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

23 Apr 2026 8-K: Other Events

On April 23, 2026, AngioDynamics, Inc. (the “Company” or “AngioDynamics”) filed a complaint commencing a patent infringement lawsuit in the United States District Court for the District of Delaware against Endovascular Engineering, Inc. ...

02 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

03 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Transition and Retirement Agreement (the “Agreement”) is dated as of February 3, 2026, by and between AngioDynamics, Inc. a Delaware corporation (the “Company”) and James C. Clemmer (the “Executive”).

14 Jan 2026 8-K: Regulation FD Disclosure

J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President & CEO

06 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

12 Nov 2025 8-K: Submission of Matters to a Vote of Security Holders

The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on November 10, 2025.

02 Oct 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

15 Jul 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

28 May 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

CREDIT AGREEMENT dated as of May 28, 2025 (as it may be amended or modified from time to time, this “Agreement”) among ANGIODYNAMICS, INC., a Delaware corporation (“AngioDynamics”), as Borrower, the other Loan Parties party hereto, the L...

02 Apr 2025 8-K: Regulation FD Disclosure

INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes.

02 Apr 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

16 Jan 2025 8-K: Regulation FD Disclosure

J.P. Morgan 43rd Annual Healthcare Conference January 16, 2025 Jim Clemmer, President & CEO

08 Jan 2025 8-K: Regulation FD Disclosure

2 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future fin...

08 Jan 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

15 Nov 2024 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

03 Oct 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

16 Jul 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support